ATLAS - Novel Transgenic Mouse Models for Therapeutic Antibody Discovery

Summary

Are you seeking a faster, more efficient way to generate therapeutic-grade monoclonal and bispecific antibodies? Transgenic mouse platforms remain the gold standard for human antibody discovery, yet access and implementation barriers often delay progress. The Jackson Laboratory’s Atlas™ Antibody Discovery Platform is breaking those barriers with novel transgenic mouse models engineered to optimize speed, diversity, and developability—empowering researchers at academic institutions and biotech companies alike.

In this webinar, you’ll discover how Atlas mice—developed in collaboration with AbTherx—are designed to accelerate timelines and reduce risk in early-stage therapeutic development. Attendees will gain insights into the functionality of both the Full Human Diversity Mouse and the Binary Fixed Light Chain Mouse, each validated against key performance metrics. Whether you're developing monospecific, bispecific, or multispecific antibodies, this session will demonstrate how Atlas can integrate seamlessly into your discovery workflows and help you bring therapies to patients faster.

In this webinar, you will:

• Discover how Atlas mice are engineered to accelerate early-stage therapeutic development timelines and reduce risk in the antibody discovery process
• Learn how Atlas can support the discovery of mono-, bi-, and multispecific antibodies
• Gain insights into the functionality of the validated Full Human Diversity and Binary Fixed Light Chain transgenic mouse models
• Understand how each model supports strong performance across key metrics such as titer, hit rate, and developability
• See how the Atlas platform integrates into existing workflows to help bring therapies to patients more efficiently and effectively

*NSG is a registered trademark in the USA and other countries